SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.

Purpose: SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs).

Methods: Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m, cisplatin 25 mg/m, and nab-paclitaxel 100 mg/m intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m and cisplatin 25 mg/m intravenously once per day on days 1 and 8 of a 21-day cycle).

Results: Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC.

Patient care in complex Sociotechnological ecosystems and learning health systems.

The learning health system (LHS) model was proposed to provide real-time, bi-directional flow of learning using data captured in health information technology systems to deliver rapid learning in healthcare delivery. As highlighted by the landmark National Academy of Medicine report "Crossing the Quality Chasm," the U.S.

Analysis of cariogenic biofilms by using a swept-source optical coherence tomography in vitro.

Objective: The objective was to measure the thickness of Streptococcus mutans (S. mutans) biofilms forming in an oral biofilm reactor (OBR) by using a noninvasive swept-source optical coherence tomography (SS-OCT) system at every 4 h time interval until 20 h and analyze the correlations with the amounts of biofilms.

Methods: S.

An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials.

Purpose: Cancer trial participants do not reflect the racial and ethnic diversity in the population of people with cancer in the United States. As a result of multiple system-, patient-, and provider-level factors, including implicit bias, cancer clinical trials are not consistently offered to all potentially eligible patients.

Materials And Methods: ASCO and ACCC evaluated the utility (pre- and post-test knowledge changes) and feasibility (completion rates, curriculum satisfaction metrics, survey questions, and interviews) of a customized online training program combined with facilitated peer-to-peer discussion designed to help research teams identify their own implicit biases and develop strategies to mitigate them.

Optimal Surface Pre-Reacted Glass Filler Ratio in a Dental Varnish Effective for Inhibition of Biofilm-Induced Root Dentin Demineralization.

A unique type of dental varnish (DV) containing surface pre-reacted glass (S-PRG) fillers of different concentrations was evaluated to determine the unpresented optimal ratio for inhibiting root dentin bio-demineralization. S-PRG DVs (10% to 40%)—10%-S, 20%-S, 30%-S, and 40%-S—were applied to bovine root dentin blocks and compared with controls—0%-f (no S-PRG) and 5%-NaF (5%-NaF). The Streptococcus mutans biofilm challenge was executed inside and outside an oral biofilm reactor for 7 days.